✦ LIBER ✦

Rationale against the drug treatment of marginal diastolic systemic hypertension

✍ Scribed by Edward D. Freis

Book ID: 113116818
Publisher: Elsevier Science
Year: 1990
Tongue: English
Weight: 469 KB
Volume: 66
Category: Article
ISSN: 0002-9149
DOI: 10.1016/0002-9149(90)90852-r

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Heterogeneity of the atherosclerotic pro

Heterogeneity of the atherosclerotic process in systemic hypertension poorly controlled by drug treatment

✍ Brigitte Maarek; Alain Ch. Simon; Jaime Levenson; Isabelle Pithois-Merli; Jean B 📂 Article 📅 1987 🏛 Elsevier Science 🌐 English ⚖ 476 KB

Effect of drug and diet treatment of mil

Effect of drug and diet treatment of mild hypertension on diastolic blood pressure. The TAIM Research Group

✍ Langford, H. G.; Davis, B. R.; Blaufox, D.; Oberman, A.; Wassertheil-Smoller, S. 📂 Article 📅 1991 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 986 KB

Implications of the U.S. Food and Drug A

Implications of the U.S. Food and Drug Administration Warning against the Use of Sildenafil for the Treatment of Pediatric Pulmonary Hypertension

✍ Abman, Steven H.; Kinsella, John P.; Rosenzweig, Erika B.; Krishnan, Usha; Kulik 📂 Article 📅 2013 🏛 American Thoracic Society 🌐 English ⚖ 470 KB

Introduction to part II of the hypertens

Introduction to part II of the hypertension symposium: Prorenin, renal hypertension diuretics and hyperlipidemia angiotensin receptors and blocking drugs a new treatment system

✍ John H. Laragh 📂 Article 📅 1976 🏛 Elsevier Science 🌐 English ⚖ 419 KB

SHORT-TERM TREATMENT OF STROKE-PRONE SPO

SHORT-TERM TREATMENT OF STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE RATS WITH AN AT1 RECEPTOR BLOCKER PROTECTS AGAINST HYPERTENSIVE END-ORGAN DAMAGE BY PROLONGED INHIBITION OF THE RENIN–ANGIOTENSIN SYSTEM

✍ Rika Hamaguchi; Kumiko Takemori; Takao Inoue; Kouichi Masuno; Hiroyuki Ito 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB

ABSORB II randomized controlled trial: A

ABSORB II randomized controlled trial: A clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: Rationale and study design

✍ Roberto Diletti; Patrick W. Serruys; Vasim Farooq; Krishnankutty Sudhir; Cecile 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 419 KB